Trials / Completed

CompletedNCT06667024

Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: 64 (actual)

Sponsor: Tanta University · Academic / Other
Sex: All
Age: 21 Years – 50 Years
Healthy volunteers: Not accepted

Summary

This study aimed to evaluate the effect of adding low doses of dexmedetomidine to hyperbaric bupivacaine during spinal anesthesia on post operative analgesia characteristics in Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

Detailed description

The anterior cruciate ligament (ACL) is injured frequently during sports participation. Arthroscopic evaluation of patients with acute traumatic hemarthrosis of the knee has repeatedly demonstrated a 60% to 70% incidence of ACL injury. Postoperative pain should be effectively treated because it represents an important component of postoperative recovery. Effective treatment serves to blunt autonomic, somatic, and endocrine reflexes with a resultant potential decrease in perioperative morbidity. Dexmedetomidine is a highly selective α2-adrenergic agonist that has been used for premedication and as an adjunct to general anesthesia. It reduces opioid and inhalational anesthetics requirements.

Conditions

Interventions

Type	Name	Description
DRUG	Hyperbaric bupivacaine	Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
DRUG	Dexmedetomidine and Hyperbaric bupivacaine	Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine

Timeline

Start date: 2023-09-01
Primary completion: 2024-04-30
Completion: 2024-04-30
First posted: 2024-10-31
Last updated: 2024-10-31

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06667024. Inclusion in this directory is not an endorsement.